

Unaudited Financial Statements for the Year Ended 31 March 2019

for

PharmaSEAL International Limited

PharmaSEAL International Limited (Registered number: 09993255)

Contents of the Financial Statements for the Year Ended 31 March 2019

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

PharmaSEAL International Limited

Company Information for the Year Ended 31 March 2019

DIRECTORS:D Cheema
N E Rotherham

Mercia Fund Management (Nominees) Ltd

SECRETARY:

REGISTERED OFFICE: Ingenuity Centre

Nottingham University Innovation Park

Triumph Rpad Nottingham NG7 2TU

REGISTERED NUMBER: 09993255 (England and Wales)

ACCOUNTANTS: M Ahmed & Co

Chartered Accountants

83 Park Road Chilwell Nottingham NG9 4DE

PharmaSEAL International Limited (Registered number: 09993255)

Balance Sheet 31 March 2019

		31.3.19		31.3.18	
	Notes	£	£	£	£
FIXED ASSETS					
Tangible assets	4		4,097		1,652
CURRENT ASSETS					
Debtors	5	122,978		45,479	
Cash at bank		888,268		361,707	
		1,011,246		407,186	
CREDITORS		, ,			
Amounts falling due within one year	6	190,835		159,116	
NET CURRENT ASSETS			820,411		248,070
TOTAL ASSETS LESS CURRENT					
LIABILITIES			824,508		249,722
CAPITAL AND RESERVES					
Called up share capital	7		3		2
Share premium	8		1,524,954		499,988
Retained earnings	8		(700,449)		(250,268)
SHAREHOLDERS' FUNDS			824,508		249,722

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2019.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2019 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors on 9 May 2019 and were signed on its behalf by:

D Cheema - Director

1. STATUTORY INFORMATION

PharmaSEAL International Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 33% on reducing balance

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2018 - 5).

Page 3 continued...

		Plant and machinery etc
		•
		etc
COST		£
At I April 2018		2,478
Additions		4,493
At 31 March 2019		$\frac{-4,755}{6,971}$
DEPRECIATION		
At I April 2018		826
Charge for year		2,048
At 31 March 2019		2,874
NET BOOK VALUE		
At 31 March 2019		4,097
At 31 March 2018		1,652
5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
	31.3.19	31.3.18
	£	£
Trade debtors	5,786	-
Tax	103,415	41,498
VAT	13,691	3,981
Prepayments	86	
	122,978	<u>45,479</u>
6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
	31.3.19	31.3.18
	£	£
Trade creditors	32,468	13,734
Other creditors	5,968	1,775
Directors' current accounts	141,999	141,999
Accrued expenses	10,400	1,608
	190,835	<u>159,116</u>

PharmaSEAL International Limited (Registered number: 09993255)

Notes to the Financial Statements - continued for the Year Ended 31 March 2019

7. CALLED UP SHARE CAPITAL

	Allotted, issu	ed and fully paid:			
	Number:	Class:	Nominal	31.3.19	31,3,18
			value:	£	£
	100,000	Ordinary	£0.00001	1	1
	55,554	A Ordinary	£0.00001	2	1
				3	2
8.	RESERVES				
			Retained	Share	
			earnings	premium	Totals
			£	£	£
	At 1 April 20	018	(250,268)	499,988	249,720
	Deficit for th	e year	(450,181)		(450,181)
	Cash share is	sue		1,024,966	1,024,966
	At 31 March	2019	(700,449)	1,524,954	824,505

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.